Search

Your search keyword '"Martényi, Ferenc"' showing total 30 results
Start Over Author "Martényi, Ferenc"
30 results on '"Martényi, Ferenc"'

1. Measuring cognition and function in the preclinical stage of Alzheimer's disease

Author

Weintraub, Sandra, Carrillo, Maria C., Farias, Sarah Tomaszewski, Goldberg, Terry E., Hendrix, James A., Jaeger, Judith, Knopman, David S., Langbaum, Jessica B., Park, Denise C., Ropacki, Michael T., Sikkes, Sietske A.M., Welsh-Bohmer, Kathleen A., Bain, Lisa J., Brashear, Robert, Budur, Kumar, Graf, Ana, Martenyi, Ferenc, Storck, Marta Segardahl, and Randolph, Christopher

Published
2018
Full Text
View/download PDF

10. DIAN-TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA

Author

Bateman, Randall J., Mills, Susan, Santacruz, Anna, Farlow, Martin R., Salloway, Stephen, Morris, John C., Benzinger, Tammie L.S., Fagan, Anne M., Goate, Alison, Hassenstab, Jason, Wang, Guoqiao, Xiong, Chengjie, Jack, Clifford R., Jr., Koeppe, Bob, Martenyi, Ferenc, Searle, Alison, Yaari, Roy, Siemers, Eric, McDade, Eric, and Clifford, David

Published
2018
Full Text
View/download PDF

11. APPROACHES TO SUBJECT RETENTION IN A PHASE 3 DELAY-OF-ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (MCI-AD) CLINICAL TRIAL: THE TOMMORROW STUDY EXPERIENCE

Author

Welsh-Bohmer, Kathleen A., Plassman, Brenda L., Chiang, Carl, Culp, Meredith, Harrigan, Patrick, O'Neil, Janet, Walter, Ryan, Haneline, Stephen, Arbuckle, Julian, Brewster, Shyama, Maruyama, Yuka, Swanson, Tom, Fitzsimmons, Dominic, Atkins, Alexandra S., Keefe, Richard S.E., Burns, Daniel K., and Martenyi, Ferenc

Published
2017
Full Text
View/download PDF

12. CLINICAL TRIALS IN THE PRECLINICAL TO MCI STAGES OF AD: CROSS-CULTURAL VALIDATION AND NORMATIVE STUDY OF THE TOMMORROW NEUROPSYCHOLOGICAL BATTERY

Author

Welsh-Bohmer, Kathleen A., Romero, Heather R., Hayden, Kathleen M., Plassman, Brenda L., Atkins, Alexandra S., Turcotte, Nicole, Keefe, Richard SE., Makeeva, Oksana A., Zhukova, Natalia G., Monsch, Andreas U., Frisoni, Giovanni B., Melikyan, Zara A., Brewster, Shyama, Chiang, Carl, Maruyama, Yuka, O'Neil, Janet, Fitzsimmons, Dominic, Runyan, Grant, Crawford, Stephen O., Oguri, Toyoko, Atkinson, Mark J., Budur, Kumar, Merikle, Elizabeth, Martenyi, Ferenc, Burns, Daniel K., and Roses, Allen D.

Published
2016
Full Text
View/download PDF

13. CHARACTERIZATION OF THE SCREENED POPULATION FOR THE TOMMORROW STUDY: A PHARMACOGENETICS-SUPPORTED CLINICAL TRIAL TO DELAY THE ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE

Author

Martenyi, Ferenc, Welsh-Bohmer, Kathleen A., Plassman, Brenda L., Harrigan, Patrick, Chiang, Carl, O'Neil, Janet, Runyan, Grant, Culp, Meredith, Lutz, Michael W., Lai, Eric, Saunders, Ann M., Haneline, Stephen, Yarnall, David, Yarbrough, Deborah, Metz, Craig, Burns, Daniel K., and Roses, Allen D.

Published
2016
Full Text
View/download PDF

16. Validation of a Multiplex Assay for Simultaneous Quantification of Amyloid-β Peptide Species in Human Plasma with Utility for Measurements in Studies of Alzheimer's Disease Therapeutics

Author

Lachno, D. Richard, primary, Emerson, Julie K., additional, Vanderstichele, Hugo, additional, Gonzales, Celedon, additional, Martényi, Ferenc, additional, Konrad, Robert J., additional, Talbot, Jayne A., additional, Lowe, Stephen L., additional, Oefinger, Paul E., additional, and Dean, Robert A., additional

Published
2012
Full Text
View/download PDF

17. A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated With ADHD in Central and Eastern Europe and Eastern Asia

Author

Goetz, Michal, primary, Yeh, Chin-Bin, additional, Ondrejka, Igor, additional, Akay, Aynur, additional, Herczeg, Ilona, additional, Dobrescu, Iuliana, additional, Kim, Boong Nyun, additional, Jin, Xingming, additional, Riley, Anne W., additional, Martényi, Ferenc, additional, Harrison, Gavan, additional, and Treuer, Tamás, additional

Published
2010
Full Text
View/download PDF

19. Attention-Deficit/Hyperactivity Disorder Diagnosis, Co-Morbidities, Treatment Patterns, and Quality of Life in a Pediatric Population in Central and Eastern Europe and Asia

Author

Martényi, Ferenc, primary, Treuer, Tamas, additional, Gau, Susan Shur-Fen, additional, Hong, Sungdo David, additional, Palaczky, Mária, additional, Šuba, Ján, additional, Tiberiu, Mircea, additional, Uhlíková, Petra, additional, Xu, Tong, additional, Zoroğlu, Salih, additional, Gadow, Kenneth D., additional, Walton, Richard, additional, and Harrison, Gavan, additional

Published
2009
Full Text
View/download PDF

27. Clonazepam for the treatment of stupor in catatonic schizophrenia.

Author

Martényi, Ferenc, Harangozó, Judit, Mód, László, Martényi, F, Harangozó, J, and Mód, L

Subjects
LETTERS to the editor, CLONAZEPAM, DRUG therapy for schizophrenia, COMA, SCHIZOPHRENIA, THERAPEUTICS
Abstract

A letter to the editor is presented in response to article about the use of clonazepam for the treatment of stupor in catatonic schizophrenia in the previous issue.

Published
1989
Full Text
View/download PDF

28. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.

Author

May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martényi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, and Mergott DJ

Subjects
Amyloid beta-Peptides blood, Amyloid beta-Peptides cerebrospinal fluid, Animals, Disease Models, Animal, Dogs, Heterocyclic Compounds, 2-Ring pharmacokinetics, Heterocyclic Compounds, 2-Ring therapeutic use, Humans, Mice, Picolinic Acids pharmacokinetics, Picolinic Acids therapeutic use, Protease Inhibitors pharmacokinetics, Protease Inhibitors therapeutic use, Alzheimer Disease drug therapy, Amyloid Precursor Protein Secretases antagonists & inhibitors, Amyloid beta-Peptides metabolism, Aspartic Acid Endopeptidases antagonists & inhibitors, Heterocyclic Compounds, 2-Ring pharmacology, Picolinic Acids pharmacology, Protease Inhibitors pharmacology
Abstract

BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry. Herein, we report the nonclinical and early clinical development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clinical trials in AD. LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclinical animal models. Similar potent and persistent amyloid β lowering was observed in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects. Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD., (Copyright © 2015 the authors 0270-6474/15/351199-12$15.00/0.)

Published
2015
Full Text
View/download PDF

29. [Three paradigms in the treatment of posttraumatic stress disorder].

Author

Martényi F

Subjects
Anti-Anxiety Agents therapeutic use, Antidepressive Agents, Second-Generation therapeutic use, Benzodiazepines therapeutic use, Combat Disorders drug therapy, Controlled Clinical Trials as Topic, Female, Fluoxetine therapeutic use, Humans, Hypnotics and Sedatives therapeutic use, Male, Piperazines, Selective Serotonin Reuptake Inhibitors therapeutic use, Stress Disorders, Traumatic, Acute drug therapy, Triazoles therapeutic use, Stress Disorders, Post-Traumatic drug therapy, Stress Disorders, Post-Traumatic prevention & control
Abstract

There are three different approaches in the pharmacological treatment of posttraumatic stress disorder (PTSD) in the published data. The most frequently implemented approach is to treat patients suffering from the diagnosis of PTSD. Both short-term acute and long-term relapse prevention treatments represent a curative paradigm: with an intention to diminish the symptoms associated with the disorder. Data about efficacy of monoamine oxidase inhibitors and selective serotonin reuptake inhibitors (SSRIs) in the treatment of PTSD are heterogeneous. Data are relatively consistent with regards of efficacy of SSRIs in the treatment of civilian, predominantly female population, regardless of the type of trauma: interpersonal or non-interpersonal trauma. Placebo controlled trial data in the treatment of combat-related PTSD are inconclusive or negative. Three recently published studies provide new approaches to the treatment of male patients, suffering from combat-related PTSD. A relatively young, recently traumatized male, combat-related population showed significant improvement for fluoxetine compared to placebo. An adjuvant 5HT2 antagonist profile may improve the SSRI effect in the treatment of PTSD: nefazodone was significantly superior compared to placebo in the treatment of combat-related PTSD, and risperidone treatment add-on to antidepressants showed significant benefits compared to antidepressant monotherapy in the treatment of combat-related PTSD. The goal of sedative paradigm is to minimize the immediate consequences of the traumatic stress, decrease the fear, anxiety and sleeplessness. Data published about benzodiazepines failed to show effectiveness in the acute management of post-traumatic mental consequences. The intention of the third treatment paradigm is characterized by the secondary prevention of PTSD. Benzodiazepines administered shortly after the traumatic event, failed to prevent the mental consequences of traumatic stress. Two small trials with propranolol administration after the trauma have been shown some benefits compared to placebo or no treatment. PTSD represents a complex disregulation of numerous neurotransmitters and neuromodulators, therefore the complex pharmacological treatment has to consider approaches beyond the current treatment regimens characterized by modulation of monoamine neurotransmission.

Published
2005

30. [Posttraumatic stress disorder (PTSD)].

Author

Martényi F

Subjects
Antidepressive Agents, Second-Generation therapeutic use, Catecholamines metabolism, Comorbidity, Controlled Clinical Trials as Topic, Crime Victims psychology, Female, Humans, Incidence, Life Change Events, Male, Paroxetine therapeutic use, Prevalence, Sertraline therapeutic use, Severity of Illness Index, Treatment Outcome, Veterans Disability Claims, Vietnam Conflict, World War I, World War II, Hypothalamo-Hypophyseal System metabolism, Pituitary-Adrenal System metabolism, Selective Serotonin Reuptake Inhibitors therapeutic use, Stress Disorders, Post-Traumatic diagnosis, Stress Disorders, Post-Traumatic drug therapy, Stress Disorders, Post-Traumatic epidemiology, Stress Disorders, Post-Traumatic etiology, Stress Disorders, Post-Traumatic metabolism, Stress Disorders, Post-Traumatic physiopathology
Abstract

The diagnosis of posttraumatic stress disorder (PTSD) has been introduced in 1980. The diagnosis, as construct raises several political, moral, legal, and compensation issues. PTSD is considered as a multisystemic dysregulation, involving the hypothalamic- pituitary - adrenal axis, adrenergic hypersensibility, and serotonergic dysfunction. The prevalence of PTSD is 1-9% in the general population, but substantially higher among victims of traumatic events: 19-70%. Placebo controlled studies provide a body of evidence concerning efficacy of selective serotonin reuptake inhibitors in the treatment of PTSD both in the acute and maintenance treatments. Studies with balanced male-female ratio suggest no gender-related differences in the clinical response, furthermore both civilians and veterans improved significantly for selective serotonin reuptake inhibitor treatment.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results